Abstract

Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with some differences related to ethnicity and age and, above all, sex and gender. Differences exist in respect to the anatomic localization of melanoma, in that it is more frequent on the trunk in men and on the lower limbs in women. A debated issue is if—and to what extent—melanoma development can be attributed to gender-specific behaviors or to biologically intrinsic differences. In the search for factors responsible for the divergences, a pivotal role of sex hormones has been observed, although conflicting results indicate the involvement of other mechanisms. The presence on the X chromosome of numerous miRNAs and coding genes playing immunological roles represents another important factor, whose relevance can be even increased by the incomplete X chromosome random inactivation. Considering the known advantages of the female immune system, a different cancer immune surveillance efficacy was suggested to explain some sex disparities. Indeed, the complexity of this picture emerged when the recently developed immunotherapies unexpectedly showed better improvements in men than in women. Altogether, these data support the necessity of further studies, which consider enrolling a balanced number of men and women in clinical trials to better understand the differences and obtain actual gender-equitable healthcare.

Highlights

  • Melanoma is the most aggressive type of skin cancer, at present accounting for 1% of total cancer deaths in Italy

  • In the last decades a steadily increasing incidence of cutaneous melanoma was observed worldwide, an important 18% decrease in mortality was recently associated with improved knowledge of biological data and the introduction of novel therapeutic approaches, melanoma reduction being the highest among the other major cancers [1]

  • androgen receptor (AR) has been recently involved in other specific molecular pathways, for example its recruitment by the SRA-like long non-coding RNA (SLNCR) to the early growth response 1 (EGR1)-bound chromatin loci to repress p21 expression [77]

Read more

Summary

Introduction

Melanoma is the most aggressive type of skin cancer, at present accounting for 1% of total cancer deaths in Italy. Cancers 2020, 12, 1819 life course being 1:66 and 1:85, respectively In both sexes, the incidence is rising, with a 4.4% increase in men and a 3.1% increase in women per year. The female immune system is more efficient than the male one, and women mount both innate and adaptive immune responses stronger than men do. This higher effectiveness on the one hand is an advantage against infectious diseases and cancers, while on the other, it makes women more prone to autoimmune diseases [12]. We speculate on the regulatory function possible played by miRNA that affects sex differences in melanoma pathogenesis at hormonal and immune levels

Sex Steroid Hormone Receptors in Melanoma
Female Hormone Activity
Male Hormone Activity
Sex and Immunity
Sex Differences and MiRNAs
Sex Differences and Response to Therapies
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call